Celontin (methsuximide) is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

Optimum dosage of Celontin (methsuximide) must be determined by trial. A suggested dosage schedule is 300 mg per day for the first week. If required, dosage may be increased thereafter at weekly intervals by 300 mg per day for the three weeks following to a daily dosage of 1.2 g. Because therapeutic effect and tolerance vary among patients, therapy with Celontin (methsuximide) must be individualized according to the response of each patient. Optimal dosage is that amount of Celontin (methsuximide) which is barely sufficient to control seizures so that side effects may be kept to a minimum. The smaller capsule (150 mg) facilitates administration to small children.

Celontin (methsuximide) may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal).

N 0071-0525-24 (P-D 525) – Celontin Capsules, #1 capsule each containing 300 mg methsuximide; bottles of 100.

N 0071-0537-24 (P-D 537) – Celontin (methsuximide) Capsules, Half-Strength, #3 capsule each containing 150 mg methsuximide; bottles of 100.

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].

Protect from light and moisture. Protect from excessive heat 40°C (104°F).

Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017. Revised July 2010

Last reviewed on RxList: 11/4/2010
This monograph has been modified to include the generic and brand name in many instances.